News Wire

There’s been a decline in real drug prices this year that may continue into next year thanks to drug payment accumulator programs. The programs discourage patients from using savings coupons to buy brand name drugs because the purchases will no longer be counted as part of the deductible. As Reuters…
Untreated mental health conditions adversely affect patients’ physical health. To address that situation, Integral Care in Austin offers some patients with mental health problems easier access to physical care and chronic disease management. Public health centers such as Integral Care are taking the…
Experts at PricewaterhouseCoopers’s Health Research Institute project that medical costs in the employer insurance market will increase by 6% next year. The good news: that falls within the range of 5.5%–7% that costs have been going up the last several years. Still the year-in, year-out cost increases…
The Centers for Medicare & Medicaid Services (CMS) has proposed significant changes to the Home Health Prospective Payment System to strengthen and modernize Medicare, drive value, and focus on individual patient needs rather than volume of care. “Today’s proposals would give doctors more time…
European researchers looked at arthritis’ patients reactions when being switched from etanercept or nfliximab. There seems to be a relationship between a patient’s willingness to switch to a biosimilar and health literacy, according to study presented by Milada Cvancarova Smastuen and colleagues…
In a move analysts of the biosimilars market have been looking for, Biogen decided to jump into a pool with both feet that it merely stuck its toe in in 2011. Biogen slapped down $700 million in its bid to buy 49.9% of Samsung Bioepis, Endpoints News reports. Apparently, the move springs from a change…
The move comes even though some of the pharma company’s rivals have promised to raise prices only once a year. The price for Pfizer’s lung-cancer treatment Xalkori, its blood-pressure pills Norvasc, and its pain capsules Lyrica will be going up, along with about 40 other of the company’s drugs,…
As might be expected, psychiatric diagnoses such as depression and anxiety are prevalent among adolescents with severe anxiety. That should not disqualify them from getting sleeve gastrectomy surgery, says a study in JAMA Pediatrics. Such adolescents are likely to lose the same amount of weight regardless…
Novartis plans to divest itself of Alcon Eye-Care, which could be valued at about $20 billion, the Wall Street Journal reports. Novartis purchased the eye care company 10 years ago for about $50 billion, but has been disappointed in its performance, though sales have picked up recently. Novartis CEO…
Public sector employees don’t have to join or pay dues to a public sector union representing them if they don’t want to, the Supreme Court ruled this week. The ruling seems as if it will weaken unions and greatly cut back on the flow of money to Democratic candidates with their health care agendas…
Fifty-eight percent of Republican voters say that they want to keep ACA a provision that prohibits denying somebody coverage for preexisting conditions, and another that prohibits charging sick people more for coverage, according to a Kaiser Health Tracking Poll. Meanwhile, 88% and 85% of Democratic…
The FDA has approved GW Research Ltd.’s Epidiolex (cannabidiol [CBD]) oral solution for the treatment of seizures associated with two rare and severe forms of epilepsy—Lennox–Gastaut syndrome and Dravet syndrome—in patients 2 years of age and older. This is the first FDA-approved drug that contains…
The FDA has permitted marketing of two catheter-based devices designed to create a connection to veins and arteries in patients with chronic kidney disease who need hemodialysis. Specifically, the FDA granted marketing authorization for the use of the Ellipsys vascular access system (Avenu Medical)…
The FDA has expanded the approval of the MiniMed 670G hybrid closed-looped system (Medtronic), a diabetes management device that is intended to automatically monitor glucose and provide appropriate basal insulin doses with little or no input from the user, to include patients 7–13 years of age with…
The FDA has approved the Eversense continuous glucose monitoring (CGM) system (Senseonics, Inc.) for use in people 18 years of age and older with diabetes. This is the first FDA-approved CGM system to include a fully implantable sensor to detect glucose, which can be worn for up to 90 days. People with…

Pages